Alexion Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating ultra-rare blood disorder characterized by complement-mediated destruction of the red blood cells (hemolysis). PNH can cause a…
EC Approves Soliris to Include Treatment of Refractory Generalized Myasthenia Gravis
Alexion Appoints Ludwig Hantson, Ph.D., as Chief Executive Officer
Alexion Pharmaceuticals, Inc. announced that its board of directors has appointed Ludwig N. Hantson, Ph.D., as chief executive officer and member of the board, effective immediately. Hantson most recently served as president and CEO of Baxalta, a spin-off as a public company from Baxter, and a global leader in the development of therapies for orphan and underserved…